Neurotransmitters excreted in the urine as biomarkers of nervous system activity: Validity and clinical applicability

Neuroscience and Biobehavioral Reviews

Volumn 35, Issue 3, 2011, Pages 635-644

  Marc, David T ^a   Ailts, Joseph W ^a   Campeau, Danielle C Ailts ^a   Bull, Michael J ^a   Olson, Kelly L ^a  

^a NeuroScience Inc   (United States)

Author keywords

ADHD; Biomarker; Depression; Inflammation; Nervous system; Neurotransmitter; Psychiatric; Urinary

Indexed keywords

4 AMINOBUTYRIC ACID; ADRENALIN; ASPARTIC ACID; CENTRAL STIMULANT AGENT; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE; GLUTAMIC ACID; HISTAMINE; IMIPRAMINE; MAPROTILINE; METHYLPHENIDATE; NEUROTRANSMITTER; NORADRENALIN; NORTRIPTYLINE; PHENETHYLAMINE; SEROTONIN;

ATTENTION DEFICIT DISORDER; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG EFFICACY; EXCRETION; HUMAN; INFLAMMATION; INTERSTITIAL CYSTITIS; KIDNEY; NERVOUS SYSTEM FUNCTION; NEUROTRANSMITTER UPTAKE; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SYSTEMIC MASTOCYTOSIS; URINALYSIS;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; NERVOUS SYSTEM; NEUROTRANSMITTER AGENTS; REPRODUCIBILITY OF RESULTS;

EID: 78649909096     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2010.07.007     Document Type: Review

References (132)

1. Acara M., Rennick B. Regulation of plasma choline by the renal tubule: bidirectional transport of choline. Am. J. Physiol. 1973, 225:1123-1128.
2. Amara S.G., Kuhar M.J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 1993, 16:73-93.
3. Anderson G.M., Dover M.A., Yang B.P., Holahan J.M., Shaywitz S.E., Marchione K.E., Hall L.M., Fletcher J.M., Shaywitz B.A. Adrenomedullary function during cognitive testing in attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2000, 39:635-643.
4. Arriza J.L., Fairman W.A., Wadiche J.I., Murdoch G.H., Kavanaugh M.P., Amara S.G. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J. Neurosci. 1994, 14:5559-5569.
5. Asano K., Lilly C.M., O'Donnell W.J., Israel E., Fischer A., Ransil B.J., Drazen J.M. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J. Allergy Clin. Immunol. 1995, 96:643-651.
6. Baker G.B., Bornstein R.A., Rouget A.C., Ashton S.E., van Muyden J.C., Coutts R.T. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol. Psychiatry 1991, 29:15-22.
7. Ballabh P., Braun A., Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 2004, 16:1-13.
8. Benazzi F. Various forms of depression. Dialogues Clin. Neurosci. 2006, 8:151-161.
9. Berry M.D. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J. Neurochem. 2004, 90:257-271.
10. Bloom, F.E., Kupfer, D.J., 1995. Psychopharmacology: the fourth generation of progress, pp. 407-471.
11. Boucher W., Stern J.M., Kotsinyan V., Kempuraj D., Papaliodis D., Cohen M.S., Theoharides T.C. Intravesical nanocrystalline silver decreases experimental bladder inflammation. J. Urol. 2008, 179:1598-1602.
12. Breidert T., Spitzenberger F., Grundemann D., Schomig E. Catecholamine transport by the organic cation transporter type 1 (OCT1). Br. J. Pharmacol. 1998, 125:218-224.
13. Busch A.E., Karbach U., Miska D., Gorboulev V., Akhoundova A., Volk C., Arndt P., Ulzheimer J.C., Sonders M.S., Baumann C., Waldegger S., Lang F., Koepsell H. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 1998, 54:342-352.
14. Busch A.E., Quester S., Ulzheimer J.C., Gorboulev V., Akhoundova A., Waldegger S., Lang F., Koepsell H. Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1. FEBS Lett. 1996, 395:153-156.
15. Castellanos F.X., Elia J., Kruesi M.J., Gulotta C.S., Mefford I.N., Potter W.Z., Ritchie G.F., Rapoport J.L. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res. 1994, 52:305-316.
16. Chekhonin V.P., Baklaushev V.P., Kogan B.M., Savchenko E.A., Lebedev S.V., Man'kovskaya I.V., Filatova T.S., Yusupova I.U., Dmitrieva T.B. Catecholamines and their metabolites in the brain and urine of rats with experimental Parkinson's disease. Bull. Exp. Biol. Med. 2000, 130:805-809.
17. Chen N.H., Reith M.E., Quick M.W. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. 2004, 447:519-531.
18. Cook I.A. Biomarkers in psychiatry: potentials, pitfalls, and pragmatics. Prim. Psychiatry 2008, 15:54-59.
19. Cormier E. Attention deficit/hyperactivity disorder: a review and update. J. Pediatr. Nurs. 2008, 23:345-357.
20. Dantonello T.M., Kuster E., Muhlbauer B. Urinary dopamine and renal handling of L-DOPA in fasted spontaneously hypertensive rats. Kidney Blood Press. Res. 1998, 21(6):438-444.
21. Davis T.P., Gehrke C.W., Gehrke C.W., Cunningham T.D., Kuo K.C., Gerhardt K.O., Johnson H.D., Williams C.H. High-performance liquid-chromatographic separation and fluorescence measurement of biogenic amines in plasma, urine, and tissue. Clin. Chem. 1978, 24:1317-1324.
22. Delahanty D.L., Nugent N.R., Christopher N.C., Walsh M. Initial urinary epinephrine and cortisol levels predict acute PTSD symptoms in child trauma victims. Psychoneuroendocrinology 2005, 30:121-128.
23. Duncan M.W., Compton P., Lazarus L., Smythe G.A. Measurement of norepinephrine and 3,4-dihydroxyphenylglycol in urine and plasma for the diagnosis of pheochromocytoma. N. Engl. J. Med. 1988, 319:136-142.
24. Eisenhofer G., Kopin I.J., Goldstein D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 2004, 56:331-349.
25. Eisenhofer G., McCarty R., Pacak K., Russ H., Schomig E. Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 354:287-294.
26. Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann. N. Y. Acad. Sci. 2002, 966:290-303.
27. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve - An integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 2009, 52:595-638.
28. Elia J., Borcherding B.G., Potter W.Z., Mefford I.N., Rapoport J.L., Keysor C.S. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin. Pharmacol. Ther. 1990, 48:57-66.
29. Engel A., von Euler U.S. Diagnostic value of increased urinary output of pheochromocytoma. Lancet 1950, 2:387.
30. Engel K., Wang J. Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol. Pharmacol. 2005, 68:1397-1407.
31. Fernstrom J.D., Fernstrom M.H. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J. Nutr. 2007, 137:1539S-1547S.
32. Francis R.C., Pickerodt P.A., Salewski L., Boemke W., Hohne C. Detection of catecholamines and metanephrines by radio-immunoassay in canine plasma. Vet. J. 2010, 183:228-231.
33. Gallowitsch-Puerta M., Pavlov V.A. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci. 2007, 80:2325-2329.
34. Gorboulev V., Ulzheimer J.C., Akhoundova A., Ulzheimer-Teuber I., Karbach U., Quester S., Baumann C., Lang F., Busch A.E., Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997, 16:871-881.
35. Graefe K.H., Friedgen B., Wolfel R., Bossle F., Russ H., Schomig E. 1,1′-Diisopropyl-2,4′-cyanine (disprocynium24), a potent uptake2 blocker, inhibits the renal excretion of catecholamines. Naunyn Schmiedebergs Arch. Pharmacol. 1997, 356:115-125.
36. Grossman F., Potter W.Z. Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. Psychiatry Res. 1999, 87:21-27.
37. Grundemann D., Babin-Ebell J., Martel F., Ording N., Schmidt A., Schomig E. Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J. Biol. Chem. 1997, 272:10408-10413.
38. Grundemann D., Koster S., Kiefer N., Breidert T., Engelhardt M., Spitzenberger F., Obermuller N., Schomig E. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J. Biol. Chem. 1998, 273:30915-30920.
39. Hanna G.L., Ornitz E.M., Hariharan M. Urinary catecholamine excretion and behavioral differences in ADHD and normal boys. J. Child Adolesc. Psychopharmacol. 1996, 6:63-73.
40. Hardebo J.E., Owman C. Characterization of the in vitro uptake of monoamines into brain microvessels. Acta Physiol. Scand. 1980, 108:223-229.
41. Hawkins R.A., O'Kane R.L., Simpson I.A., Vina J.R. Structure of the blood-brain barrier and its role in the transport of amino acids. J. Nutr. 2006, 136:218S-226S.
42. Hayer-Zillgen M., Bruss M., Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 2002, 136:829-836.
43. Henderson J. Ernest starling and 'Hormones': an historical commentary. J. Endocrinol. 2005, 184:5-10.
44. Hermens D.F., Rowe D.L., Gordon E., Williams L.M. Integrative neuroscience approach to predict ADHD stimulant response. Expert. Rev. Neurother. 2006, 6:753-763.
45. Hershko A.Y., Dranitzki Z., Ulmanski R., Levi-Schaffer F., Naparstek Y. Constitutive hyperhistaminaemia: a possible mechanism for recurrent anaphylaxis. Scand. J. Clin. Lab. Invest. 2001, 61:449-452.
46. Hogan A.D., Schwartz L.B. Markers of mast cell degranulation. Methods 1997, 13:43-52.
47. Holsboer F. How can we realize the promise of personalized antidepressant medicines?. Nat. Rev. Neurosci. 2008, 9:638-646.
48. Hosoya K., Sugawara M., Asaba H., Terasaki T. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J. Neurochem. 1999, 73:1206-1211.
49. Hubner C., Wedding U., Strater J., Limberg B., Stremmel W. Clinical stable systemic mastocytosis with interferon alpha-2b therapy. J. Intern. Med. 1997, 241:529-533.
50. Hughes J.W., Watkins L., Blumenthal J.A., Kuhn C., Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J. Psychosom. Res. 2004, 57:353-358.
51. Huisman H., Wynveen P., Setter P.W. Studies on the immune response and preparation of antibodies against a large panel of conjugated neurotransmitters and biogenic amines: specific polyclonal antibody response and tolerance. J. Neurochem. 2010, 112:829-841.
52. Huszti Z., Deli M.A., Joo F. Carrier-mediated uptake and release of histamine by cultured rat cerebral endothelial cells. Neurosci. Lett. 1995, 184:185-188.
53. Joyce P.R., Fergusson D.M., Woollard G., Abbott R.M., Horwood L.J., Upton J. Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. J. Affect. Disord. 1995, 33:233-243.
54. Kagedal B., Goldstein D.S. Catecholamines and their metabolites. J. Chromatogr. 1988, 429:177-233.
55. Kakee A., Takanaga H., Terasaki T., Naito M., Tsuruo T., Sugiyama Y. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier. J. Neurochem. 2001, 79:110-118.
56. Karbach U., Kricke J., Meyer-Wentrup F., Gorboulev V., Volk C., Loffing-Cueni D., Kaissling B., Bachmann S., Koepsell H. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am. J. Physiol. Renal Physiol. 2000, 279:F679-F687.
57. Kekuda R., Prasad P.D., Wu X., Wang H., Fei Y.J., Leibach F.H., Ganapathy V. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J. Biol. Chem. 1998, 273:15971-15979.
58. Koepsell H., Busch A., Gorboulev V., Arndt P. Structure and function of renal organic cation transporters. News Physiol. Sci. 1998, 13:11-16.
59. Koepsell H., Gorboulev V., Arndt P. Molecular pharmacology of organic cation transporters in kidney. J. Membr. Biol. 1999, 167:103-117.
60. Kopp U., Bradley T., Hjemdahl P. Renal venous outflow and urinary excretion of norepinephrine, epinephrine, and dopamine during graded renal nerve stimulation. Am. J. Physiol. 1983, 244:E52-E60.
61. Koslow S.H., Maas J.W., Bowden C.L., Davis J.M., Hanin I., Javaid J. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Arch. Gen. Psychiatry 1983, 40:999-1010.
62. Koslow S.H., Maas J.W., Bowden C.L., Davis J.M., Hanin I., Javaid J. Tricyclic antidepressant washout effects on cerebrospinal fluid and urinary monoamine and metabolites. Arch. Gen. Psychiatry 1986, 43:1012-1013.
63. Kotzailias N., Marker M., Jilma B. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2004, 24:536-539.
64. Kudva Y.C., Sawka A.M., Young W.F. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J. Clin. Endocrinol. Metab. 2003, 88:4533-4539.
65. Kusaga A., Yamashita Y., Koeda T., Hiratani M., Kaneko M., Yamada S., Matsuishi T. Increased urine phenylethylamine after methylphenidate treatment in children with ADHD. Ann. Neurol. 2002, 52:372-374.
66. Lamale L.M., Lutgendorf S.K., Zimmerman M.B., Kreder K.J. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology 2006, 68:702-706.
67. Lechin F., van der Dijs D.B. Central nervous system circuitry and peripheral neural sympathetic activity responsible for essential hypertension. Curr. Neurovasc. Res. 2006, 3:307-325.
68. Lechin F., van der Dijs D.B., Lechin M.E. Plasma neurotransmitters and functional illness. Psychother. Psychosom. 1996, 65:293-318.
69. Le-Niculescu H., Kurian S.M., Yehyawi N., Dike C., Patel S.D., Edenberg H.J., Tsuang M.T., Salomon D.R., Nurnberger J.I., Niculescu A.B. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol. Psychiatry 2008, 14:156-174.
70. Lepschy M., Rettenbacher S., Touma C., Palme R.G. Excretion of catecholamines in rats, mice and chicken. J. Comp. Physiol. [B] 2008, 178:629-636.
71. Lynn-Bullock C.P., Welshhans K., Pallas S.L., Katz P.S. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats. J. Chem. Neuroanat. 2004, 27:129-138.
72. Maas J.W., Koslow S.H., Davis J., Katz M., Frazer A., Bowden C.L., Berman N., Gibbons R., Stokes P., Landis D.H. Catecholamine metabolism and disposition in healthy and depressed subjects. Arch. Gen. Psychiatry 1987, 44:337-344.
73. Maas J.W., Landis D.H. A technique for assaying the kinetics of norepinephrine metabolism in the central nervous system in vivo. Psychosom. Med. 1965, 28:247-256.
74. Manyam B.V., Hare T.A. Cerebrospinal fluid GABA measurements: basic and clinical considerations. Clin. Neuropharmacol. 1983, 6:25-36.
75. Matsuda F., Hayashi T., Naruse H. A study on the origins of urinary serotonin and tryptamine. Tokai J. Exp. Clin. Med. 1991, 16:245-252.
76. Mayer E.A., Tillisch K., Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment. Pharmacol. Ther. 2006, 24:919-933.
77. Moleman P., Tulen J.H., Blankestijn P.J., Man in't Veld A.J., Boomsma F. Urinary excretion of catecholamines and their metabolites in relation to circulating catecholamines. Six-hour infusion of epinephrine and norepinephrine in healthy volunteers. Arch. Gen. Psychiatry 1992, 49:568-572.
78. Mooney J.J., Cole J.O., Schatzberg A.F., Gerson B., Schildkraut J.J. Pretreatment urinary MHPG levels as predictors of antidepressant responses to alprazolam. Am. J. Psychiatry 1985, 142:366-367.
79. Mooney J.J., Samson J.A., Hennen J., Pappalardo K., McHale N., Alpert J., Koutsos M., Schildkraut J.J. Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3). J. Psychiatr. Res. 2008, 42:605-611.
80. Mooney J.J., Schatzberg A.F., Cole J.O., Kizuka P.P., Salomon M., Lerbinger J., Pappalardo K.M., Gerson B., Schildkraut J.J. Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase. Biol. Psychiatry 1988, 23:543-559.
81. Mooney J.J., Schatzberg A.F., Cole J.O., Samson J.A., Waternaux C., Gerson B., Pappalardo K.M., Schildkraut J.J. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. J. Clin. Psychopharmacol. 1991, 11:339-343.
82. Moyer T.P., Jiang N.S., Tyce G.M., Sheps S.G. Analysis for urinary catecholamines by liquid chromatography with amperometric detection: methodology and clinical interpretation of results. Clin. Chem. 1979, 25:256-263.
83. Murdoch R.D., Youlten L.J., Williams A.J., Howland K. Plasma concentrations and urinary excretion of histamine after inhalation and subcutaneous injection of histamine. Br. J. Clin. Pharmacol. 1993, 35:171-177.
84. Myers G., Donlon M., Kaliner M. Measurement of urinary histamine: development of methodology and normal values. J. Allergy Clin. Immunol. 1981, 67:305-311.
85. Nakatani Y., Sato-Suzuki I., Tsujino N., Nakasato A., Seki Y., Fumoto M., Arita H. Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur. J. Neurosci. 2008, 27:2466-2472.
86. Nemeroff C.B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J. Psychiatr. Res. 2007, 41:189-206.
87. Nigrovic L.E., McQueen A.A., Neuman M.I. Lumbar puncture success rate is not influenced by family-member presence. Pediatrics 2007, 120:e777-e782.
88. Nishiwaki F., Kuroda K., Inoue Y., Endo G. Determination of histamine, 1-methylhistamine and N-methylhistamine by capillary electrophoresis with micelles. Biomed. Chromatogr. 2000, 14:184-187.
89. Noshiro T., Saigusa T., Way D., Dorward P.K., McGrath B.P. Norepinephrine spillover faithfully reflects renal sympathetic nerve activity in conscious rabbits. Am. J. Physiol. 1991, 261:F44-F50.
90. Ohtsuki S. New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system. Biol. Pharm. Bull. 2004, 27:1489-1496.
91. Okumura T., Nakajima Y., Matsuoka M., Takamatsu T. Study of salivary catecholamines using fully automated column-switching high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1997, 694:305-316.
92. Otte C., Neylan T.C., Pipkin S.S., Browner W.S., Whooley M.A. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am. J. Psychiatry 2005, 162:2139-2145.
93. Panholzer T.J., Beyer J., Lichtwald K. Coupled-column liquid chromatographic analysis of catecholamines, serotonin, and metabolites in human urine. Clin. Chem. 1999, 45:262-268.
94. Pardridge W.M. Blood-brain barrier biology and methodology. J. Neurovirol. 1999, 5:556-569.
95. Pliszka S.R., Maas J.W., Javors M.A., Rogeness G.A., Baker J. Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety. J. Am. Acad. Child Adolesc. Psychiatry 1994, 33:1165-1173.
96. Rosano T.G., Swift T.A., Hayes L.W. Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma. Clin. Chem. 1991, 37:1854-1867.
97. Roy A., Linnoila M., Karoum F., Pickar D. Relative activity of metabolic pathways for norepinephrine in endogenous depression. Acta Psychiatr. Scand. 1986, 73:624-628.
98. Roy A., Pickar D., De J.J., Karoum F., Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch. Gen. Psychiatry 1988, 45:849-857.
99. Roy A., Pickar D., Douillet P., Karoum F., Linnoila M. Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls. Psychol. Med. 1986, 16:541-546.
100. Roy A., Pollack S. Are cerebrospinal fluid or urinary monoamine metabolite measures stronger correlates of suicidal behavior in depression?. Neuropsychobiology 1994, 29:164-167.
101. Rubin L.L., Staddon J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 1999, 22:11-28.
102. Schatzberg A.F. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. J. Clin. Psychiatry 1998, 59(Suppl. 14):15-18.
103. Schildkraut J.J., Orsulak P.J., Schatzberg A.F., Gudeman J.E., Cole J.O., Rohde W.A., LaBrie R.A. Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Arch. Gen. Psychiatry 1978, 35:1427-1433.
104. Schildkraut J.J., Schatzberg A.F., Samson J.A., Rosenbaum A., Bowden C.L. Norepinephrine output and metabolism in depressed patients during antidepressant treatments. Clin. Neuropharmacol. 1992, 15(Suppl. 1 Pt A):323A-324A.
105. Schwartz L.B. Effector cells of anaphylaxis: mast cells and basophils. Novartis. Found. Symp. 2004, 257:65-74.
106. Schwarz E., Bahn S. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br. J. Pharmacol. 2008, 153(Suppl. 1):S133-S136.
107. Seegal R.F., Brosch K.O., Bush B. High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. J. Chromatogr. 1986, 377:131-144.
108. Skoner D.P., Gentile D.A., Fireman P., Cordoro K., Doyle W.J. Urinary histamine metabolite elevations during experimental influenza infection. Ann. Allergy Asthma Immunol. 2001, 87:303-306.
109. Swann A.C., Koslow S.H., Katz M.M., Maas J.W., Javaid J., Secunda S.K., Robins E. Lithium carbonate treatment of mania. Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch. Gen. Psychiatry 1987, 44:345-354.
110. Szabo A., Billett E., Turner J. Phenylethylamine, a possible link to the antidepressant effects of exercise?. Br. J. Sports Med. 2001, 35:342-343.
111. Takanaga H., Ohtsuki S., Hosoya K., Terasaki T. GAT2/BGT-1 as a system responsible for the transport of gamma-aminobutyric acid at the mouse blood-brain barrier. J. Cereb. Blood Flow Metab. 2001, 21:1232-1239.
112. Takasaki Y., Tsukasaki K., Jubashi T., Tomonaga M., Kamihira S., Makiyama K. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha. Intern. Med. 1998, 37:484-488.
113. Tamai I., Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 2000, 89:1371-1388.
114. Tang A.W. A practical guide to anaphylaxis. Am. Fam. Physician 2003, 68:1325-1332.
115. von Euler U.S., Hellner S. Excretion of noradrenaline, adrenaline, and hydroxytyramine in urine. Acta Physiol. Scand. 1951, 22:160-167.
116. von Euler U.S., Hellner-Bjorkman S., Orwen I. Diurnal variations in the excretion of free and conjugated noradrenaline and adrenaline in urine from healthy subjects. Acta Physiol. Scand. Suppl. 1955, 33:10-16.
117. von Euler U.S., Luft R. Noradrenaline output in urine after infusion in man. Br. J. Pharmacol. Chemother. 1951, 6:286-288.
118. Wa T.C., Burns N.J., Williams B.C., Freestone S., Lee M.R. Blood and urine 5-hydroxytryptophan and 5-hydroxytryptamine levels after administration of two 5-hydroxytryptamine precursors in normal man. Br. J. Clin. Pharmacol. 1995, 39:327-329.
119. Wakayama K., Ohtsuki S., Takanaga H., Hosoya K., Terasaki T. Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells. Neurosci. Res. 2002, 44:173-180.
120. Westermann J., Hubl W., Kaiser N., Salewski L. Simple, rapid and sensitive determination of epinephrine and norepinephrine in urine and plasma by non-competitive enzyme immunoassay, compared with HPLC method. Clin. Lab. 2002, 48:61-71.
121. Westphal S.A. Diagnosis of a pheochromocytoma. Am. J. Med. Sci. 2005, 329:18-21.
122. Wong D.F., Potter W.Z., Brasic J.R. Proof of concept: functional models for drug development in humans. Neuropsychopharmacology: Fifth Generation of progress 2002, 457-473. Lippincott Williams & Wilkins, Philadelphia. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
123. Wood J.H. Neurochemical analysis of cerebrospinal fluid. Neurology 1980, 30:645-651.
124. Wu X., Huang W., Ganapathy M.E., Wang H., Kekuda R., Conway S.J., Leibach F.H., Ganapathy V. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am. J. Physiol. Renal Physiol. 2000, 279:F449-F458.
125. Wu X., Kekuda R., Huang W., Fei Y.J., Leibach F.H., Chen J., Conway S.J., Ganapathy V. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J. Biol. Chem. 1998, 273:32776-32786.
126. Wurtman R.J. Nutrients affecting brain composition and behavior. Integr. Psychiatry 1987, 5:226-238.
127. Wurtman Effects of dietary amino acids, carbohydrates, and choline on neurotransmitter synthesis. Mt. Sinai J. Med. 1988, 55:75-86.
128. Yabuuchi H., Tamai I., Nezu J., Sakamoto K., Oku A., Shimane M., Sai Y., Tsuji A. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 1999, 289:768-773.
129. Yamatodani A. [Plasma and urinary histamine assay and the clinical significance]. Nippon Rinsho 1990, 48(Suppl.):171-174.
130. Zametkin A.J., Hamburger S.D. The effect of methylphenidate on urinary catecholamine excretion in hyperactivity: a partial replication. Biol. Psychiatry 1988, 23:350-356.
131. Zametkin A.J., Karoum F., Linnoila M., Rapoport J.L., Brown G.L., Chuang L.W., Wyatt R.J. Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine. Arch. Gen. Psychiatry 1985, 42:251-255.
132. Zarate A., Saucedo R. On the centennial of hormones. A tribute to Ernest H. Starling and William M. Bayliss. Gac. Med. Mex. 2005, 141:437-439.